Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation
Pre-surgical studies allow study of the relationship between mutations and response of oestrogen receptor-positive (ER+) breast cancer to aromatase inhibitors (AIs) but have been limited to small biopsies. Here in phase I of this study, we perform exome sequencing on baseline, surgical core-cuts and blood from 60 patients (40 AI treated, 20 controls). In poor responders (based on Ki67 change), we find significantly more somatic mutations than good responders. Subclones exclusive to baseline or surgical cores occur in ∼30% of tumours. In phase II, we combine targeted sequencing on another 28 treated patients with phase I. We find six genes frequently mutated: PIK3CA, TP53, CDH1, MLL3, ABCA13 and FLG with 71% concordance between paired cores. TP53 mutations are associated with poor response. We conclude that multiple biopsies are essential for confident mutational profiling of ER+ breast cancer and TP53 mutations are associated with resistance to oestrogen deprivation therapy.
Journal Article
Gellert, Pascal
67d193df-3da3-4877-8b6e-24a0703ea65f
Segal, Corrinne V
a23843fb-1d02-404f-92eb-ecb336e3a86c
Gao, Qiong
90f7911d-0215-471c-aada-74540e6cb3ef
López-Knowles, Elena
ef44240d-77e2-4779-9053-3ffaf3055378
Martin, Lesley-Ann
eebfd860-c253-40e3-a3ad-0d499e832005
Dodson, Andrew
187ce9c5-2c86-4122-985e-4aaacda86c4a
Li, Tiandao
6aa62ded-64dd-4fec-ae66-8358577ec5a6
Miller, Christopher A
790d6bfe-a7ea-4f3a-af69-8ad666fbcc86
Lu, Charles
81cc0d90-b8d6-47f8-84c5-ea6348d07b85
Mardis, Elaine R
3ff01ec0-edcc-491d-9247-50aef4783359
Gillman, Alexa
ffb3db21-f6f9-436b-90a1-1356c470fa8b
Morden, James
13991e60-4a55-4e17-8fc2-b03bcc33113c
Graf, Manuela
33d100b1-1b75-4bac-a889-c85a2f09defe
Sidhu, Kally
b7556b3e-edff-4474-be35-7c6701a28635
Evans, Abigail
fd8a598c-6e5a-4292-96d8-3f754be4518b
Shere, Michael
d9791a81-4649-4c15-95d3-aff2e79a92f1
Holcombe, Christopher
e10e54d6-3370-45be-a43f-59a381f4391c
McIntosh, Stuart A
64e6b959-5e9c-4755-a352-4554f625ec2b
Bundred, Nigel
81763280-2028-45e7-82ac-d04f3c04c5dc
Skene, Anthony
65bb0e2f-77a8-4b01-bc42-ce714dc24b94
Maxwell, William
f6c18ae3-d59c-4891-a6f5-4cdde530a065
Robertson, John
8cf915e7-d52b-4533-babf-2b8f3bbc3a62
Bliss, Judith M
32216b02-f161-4aa5-8a6c-7777c440a458
Smith, Ian
e28e3644-e801-4ca9-9449-16a559e66f03
Dowsett, Mitch
39a1ba62-b1de-478b-bcc6-0a169c415e8e
Cutress, Ramsey
68ae4f86-e8cf-411f-a335-cdba51797406
POETIC Trial Management Group and Trialists
Gellert, Pascal
67d193df-3da3-4877-8b6e-24a0703ea65f
Segal, Corrinne V
a23843fb-1d02-404f-92eb-ecb336e3a86c
Gao, Qiong
90f7911d-0215-471c-aada-74540e6cb3ef
López-Knowles, Elena
ef44240d-77e2-4779-9053-3ffaf3055378
Martin, Lesley-Ann
eebfd860-c253-40e3-a3ad-0d499e832005
Dodson, Andrew
187ce9c5-2c86-4122-985e-4aaacda86c4a
Li, Tiandao
6aa62ded-64dd-4fec-ae66-8358577ec5a6
Miller, Christopher A
790d6bfe-a7ea-4f3a-af69-8ad666fbcc86
Lu, Charles
81cc0d90-b8d6-47f8-84c5-ea6348d07b85
Mardis, Elaine R
3ff01ec0-edcc-491d-9247-50aef4783359
Gillman, Alexa
ffb3db21-f6f9-436b-90a1-1356c470fa8b
Morden, James
13991e60-4a55-4e17-8fc2-b03bcc33113c
Graf, Manuela
33d100b1-1b75-4bac-a889-c85a2f09defe
Sidhu, Kally
b7556b3e-edff-4474-be35-7c6701a28635
Evans, Abigail
fd8a598c-6e5a-4292-96d8-3f754be4518b
Shere, Michael
d9791a81-4649-4c15-95d3-aff2e79a92f1
Holcombe, Christopher
e10e54d6-3370-45be-a43f-59a381f4391c
McIntosh, Stuart A
64e6b959-5e9c-4755-a352-4554f625ec2b
Bundred, Nigel
81763280-2028-45e7-82ac-d04f3c04c5dc
Skene, Anthony
65bb0e2f-77a8-4b01-bc42-ce714dc24b94
Maxwell, William
f6c18ae3-d59c-4891-a6f5-4cdde530a065
Robertson, John
8cf915e7-d52b-4533-babf-2b8f3bbc3a62
Bliss, Judith M
32216b02-f161-4aa5-8a6c-7777c440a458
Smith, Ian
e28e3644-e801-4ca9-9449-16a559e66f03
Dowsett, Mitch
39a1ba62-b1de-478b-bcc6-0a169c415e8e
Cutress, Ramsey
68ae4f86-e8cf-411f-a335-cdba51797406